Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

Other changes at Pfizer include Mikael Dolsten ... He will also cover business analytics, global commercial operations and patient and health impact, among others. Pfizer’s Consumer Healthcare ...

This caused Pfizer to change its tactics ... a generics behemoth with annual sales of around $19 to $20 billion and operations in 165 markets around the word. This era, though, was also marked ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

Pfizer can get out of its recent troubles thanks to a deep pipeline and cost-cutting efforts. Medical Properties Trust has ...

Pfizer reported an impressive 85% year-on-year (YoY) growth in net profit, which rose to Rs 331 crore compared to Rs 179 crore in the same quarter last year. Revenue from operations also increased ...

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. today announced longer-term follow-up results from an open-label extension of the Phase 3 ARCHES ...